IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Paused · Phase 1
Conditions studied: Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
In brief
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.
Key facts
- Study ID
- NCT06677710
- Run by
- Indapta Therapeutics, INC.
- People needed
- 34
- Starts
- 2026-06-30
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2025-04-30
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University — Stanford, California, United States
- University of Colorado Hospital — Aurora, Colorado, United States
- AdventHealth Orlando - Adventist Health System/Sunbelt, Inc. — Orlando, Florida, United States
- Kansas University Medical Center — Kansas City, Kansas, United States
- Washington University in St. Louis — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.